Michael Shetzline Ironwood Pharmaceuticals Inc (IRWD) insider trading activity

Michael Shetzline is SVP, CMO, Head-Res&Drug of IRONWOOD PHARMACEUTICALS INC. Currently has a direct ownership of 461,943 shares of IRWD, which is worth approximately $1.08 Million. The most recent transaction as insider was on Jan 17, 2025, when has been sold 48,224 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 462K

11.66% 3M change

21.85% 12M change

Total Value Held $1.08 Million

Michael Shetzline Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 17 2025	BUY Grant, award, or other acquisition	-	48,224 Added 9.45%	461,943 Class A Common Stock
May 20 2024	SELL Open market or private sale	$104,025 $6.45 p/Share	16,128 Reduced 3.75%	413,719 Class A Common Stock
Mar 08 2024	BUY Exercise of conversion of derivative security	-	34,936 Added 7.52%	429,847 Class A Common Stock
Feb 12 2024	SELL Open market or private sale	$588,538 $15.24 p/Share	38,618 Reduced 10.19%	340,484 Class A Common Stock
Feb 12 2024	BUY Grant, award, or other acquisition	-	54,427 Added 12.11%	394,911 Class A Common Stock
Jan 17 2024	BUY Grant, award, or other acquisition	-	57,971 Added 13.26%	379,102 Class A Common Stock
May 22 2023	SELL Open market or private sale	$104,478 $10.12 p/Share	10,324 Reduced 3.11%	321,131 Class A Common Stock
Mar 08 2023	BUY Grant, award, or other acquisition	-	69,869 Added 17.41%	331,455 Class A Common Stock
Feb 28 2023	SELL Open market or private sale	$111,448 $11.31 p/Share	9,854 Reduced 3.63%	261,586 Class A Common Stock
Feb 27 2023	SELL Open market or private sale	$108,029 $11.41 p/Share	9,468 Reduced 3.37%	271,440 Class A Common Stock
Jan 17 2023	BUY Grant, award, or other acquisition	-	14,663 Added 4.96%	280,908 Class A Common Stock
May 23 2022	SELL Open market or private sale	$121,704 $11.5 p/Share	10,583 Reduced 3.82%	266,245 Class A Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	81,448 Added 22.73%	276,828 Class A Common Stock
Feb 28 2022	SELL Open market or private sale	$189,627 $10.77 p/Share	17,607 Reduced 8.27%	195,380 Class A Common Stock
Jan 19 2022	BUY Grant, award, or other acquisition	-	29,326 Added 12.1%	212,987 Class A Common Stock
Nov 23 2021	SELL Open market or private sale	$159,526 $11.58 p/Share	13,776 Reduced 6.98%	183,661 Class A Common Stock
May 24 2021	SELL Open market or private sale	$25,443 $12.25 p/Share	2,077 Reduced 1.04%	197,437 Class A Common Stock
Mar 26 2021	BUY Grant, award, or other acquisition	-	38,655 Added 16.23%	199,514 Class A Common Stock
Feb 26 2021	SELL Open market or private sale	$40,439 $9.11 p/Share	4,439 Reduced 2.69%	160,859 Class A Common Stock
Feb 22 2021	BUY Grant, award, or other acquisition	-	58,252 Added 26.06%	165,298 Class A Common Stock

Michael Shetzline

SVP, CMO, Head-Res&Drug

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IRWD shares.

Notify only if

Value

Insider Trading

Get notified when an Ironwood Pharmaceuticals Inc insider buys or sells IRWD shares.

Notify only if

Operation

Value

Type

News

Receive news related to IRONWOOD PHARMACEUTICALS INC

Track Activities on IRWD

Account